NASDAQ : KROS
Keros Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 11.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 225.24M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 209.77M |
| Enterprise Value | -32.11M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 19.83M |
| Shares Outstanding | 19.83M |
| Shares Change (YoY) | -33.15% |
| Shares Change (QoQ) | +0.87% |
| Owned by Insiders (%) | 3.26% |
| Owned by Institutions (%) | 90.70% |
| Float | 17.77M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.18 |
| Forward PS | 14.82 |
| PB Ratio | 0.83 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 21.96 |
| Quick Ratio | 21.47 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -17.16% |
| Return on Assets (ROA) | -11.78% |
| Return on Invested Capital (ROIC) | -481.72% |
| Return on Capital Employed (ROCE) | -35.75% |
| Weighted Average Cost of Capital (WACC) | 9.71% |
| Revenue Per Employee | $163,196 |
| Profits Per Employee | -$903,902 |
| Employee Count | 92 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -2.94M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.12 |
| 52-Week Price Change | -26.60% |
| 50-Day Moving Average | 11.27 |
| 200-Day Moving Average | 12.06 |
| Relative Strength Index (RSI) | 45.93 |
| Average Volume (20 Days) | 164,758 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.14M |
| Short Previous Month | 1.15M |
| Short % of Shares Out | 5.73% |
| Short % of Float | 6.40% |
| Short Ratio (days to cover) | 5.91 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 15.01M |
| Gross Profit | -58.35M |
| Operating Income | -98.47M |
| Pretax Income | -86.10M |
| Net Income | -83.16M |
| EBITDA | -96.87M |
| EBIT | -98.47M |
| Loss Per Share | -$3.10 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 257.61M |
| Total Debt | 15.72M |
| Net Cash | 241.88M |
| Net Cash Per Share | $12.20 |
| Equity (Book Value) | 262.32M |
| Book Value Per Share | 13.23 |
| Working Capital | 254.73M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -47.99M |
| Capital Expenditures | -494,000 |
| Depreciation & Amortization | 1.60M |
| Net Borrowing | n/a |
| Free Cash Flow | -48.49M |
| FCF Per Share | -$2.45 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -655.84% |
| Pretax Margin | -573.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 33.15% |
| Shareholder Yield | 33.15% |
| Earnings Yield | -29.34% |
| FCF Yield | -22.77% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $19.83 |
| Price Target Difference | 87.43% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -43.21% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 8.22 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |